Medivir AB (publ) EBIT

Medivir AB (publ) (0GP7.L) currently reports a EBIT of $-69M as of December 2022. That compares with $-38M in the prior-year period — down 80.8% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Medivir AB (publ)'s EBIT history and peer comparisons.

Medivir AB (publ)'s EBIT decreased from $-38M to $-69M — a 80.8% year-over-year decrease (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Medivir AB (publ)'s EBIT of $-69M is lower than the Healthcare sector average of $110B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Medivir AB (publ) reported $-69M in EBIT as of December 2022. That compares with $-38M in the prior-year period — down 80.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-69M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Medivir AB (publ), and consider following 0GP7.L for alerts when major investors trade the stock.